1. Show article details.

    BRIEF-F-Star Therapeutics Announces License Agreement With Janssen

    Reuters – 8:05 AM ET 10/20/2021

    F-Star Therapeutics Inc (FSTX): * F-STAR THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH JANSSEN TO DEVELOP AND COMMERCIALIZE MULTIPLE NEXT GENERATION BISPECIFIC ANTIBODY THERAPEUTICS. * F-Star Therapeutics Inc (FSTX) - JANSSEN WILL BE RESPONSIBLE FOR ALL RESEARCH, DEVELOPMENT, AND COMMERCIALIZATION ACTIVITIES UNDER AGREEMENT.

  2. Show article details.

    U.S. administers 409.4 mln doses of COVID-19 vaccines - CDC

    Reuters – 5:46 PM ET 10/19/2021

    The United States has administered 409,438,987 doses of COVID-19 vaccines in the country as of Tuesday morning and distributed 495,844,635 doses, the U.S. Centers for Disease Control and Prevention said. Those figures are up from the 408,797,942 vaccine doses the CDC said had gone into arms by Oct. 18 out of 494,655,075 doses delivered.

  3. Show article details.

    GLOBAL MARKETS-Stocks gain as earnings provide some optimism; 10-yr yield climbs

    Reuters – 5:17 PM ET 10/19/2021

    * All three major U.S. stock indexes end higher. * Oil, gold futures rise. * Dollar stumbles. By Caroline Valetkevitch. Stock indexes around the world jumped on Tuesday as U.S. technology shares extended recent gains and earnings reports were upbeat, while the 10-year U.S. Treasury yield rose to its highest in more than four months.

  4. Show article details.

    US STOCKS-Wall Street ends higher as investors bet on positive earnings season

    Reuters – 4:00 PM ET 10/19/2021

    By Shreyashi Sanyal and Sinéad Carew. U.S. stock indexes closed higher on Tuesday with the biggest boosts from the technology and healthcare sectors as investors appeared to bet on solid quarterly reports even as some worried that it was too early to celebrate. In its fifth straight session of gains, the benchmark S&P 500 index neared its early September record high.

  5. Show article details.

    US STOCKS-Wall Street rises as investors bet on positive earnings season

    Reuters – 2:56 PM ET 10/19/2021

    * J&J raises 2021 profit forecast after Q3 earnings beat. * Insurer Travelers rises after beating profit estimates. * Walmart (WMT) up on entering GS 'conviction list' * P&G falls after warning on higher supply chain costs. * Indexes up: Dow 0.31%, S&P 0.53%, Nasdaq 0.54% By Shreyashi Sanyal and Sinéad Carew.

  6. Show article details.

    U.S. homebuilding stumbles as supply constraints mount

    Reuters – 12:11 PM ET 10/19/2021

    * Housing starts fall 1.6% in September; August revised down. * Single-family starts unchanged; multifamily drop 5.0% * Building permits tumble 7.7%; single family decrease 0.9% By Lucia Mutikani.

  7. Show article details.

    US STOCKS-Wall Street rises as earnings whip up risk appetite

    Reuters – 10:16 AM ET 10/19/2021

    * J&J raises 2021 profit forecast after Q3 earnings beat. * Insurer Travelers rises after beating profit estimates. * Walmart (WMT) up on entering GS 'conviction list' * P&G falls after warning on higher supply chain costs. * Indexes up: Dow 0.31%, S&P 0.39%, Nasdaq 0.44% By Shreyashi Sanyal.

  8. Show article details.

    US STOCKS-Earnings whip up risk appetite as Wall St sees higher open

    Reuters – 9:08 AM ET 10/19/2021

    * J&J raises 2021 profit forecast after Q3 earnings beat. * Walmart (WMT) up after entering GS 'conviction list' * P&G falls on higher supply chain costs warning. * Futures up: Dow 0.42%, S&P 0.42%, Nasdaq 0.34% By Shreyashi Sanyal.

  9. Show article details.

    US STOCKS-Futures rise as upbeat earnings boost risk appetite

    Reuters – 7:09 AM ET 10/19/2021

    * J&J raises 2021 profit forecast after Q3 earnings beat. * Walmart (WMT) rises on entering GS "conviction list" * Futures up: Dow 0.42%, S&P 0.45%, Nasdaq 0.34% By Shreyashi Sanyal. Oct 19 - U.S. stock index futures rose on Tuesday as an upbeat profit forecast from Johnson & Johnson (JNJ) added to the positive momentum in corporate earnings generated by big banks last week.

  10. Show article details.

    J&J raises 2021 profit view, keeps vaccine sales outlook unchanged

    Reuters – 6:36 AM ET 10/19/2021

    Johnson & Johnson (JNJ) on Tuesday raised its adjusted profit forecast for 2021, even as it stuck to its outlook of $2.5 billion in sales from its COVID-19 vaccine this year. The company raised its annual adjusted earnings forecast to between $9.77 per share and $9.82 per share, from its prior estimates of $9.60 to $9.70 per share.

  11. Show article details.

    BRIEF-Johnson & Johnson Posts Q3 EPS $1.37

    Reuters – 6:34 AM ET 10/19/2021

    Johnson & Johnson (JNJ): * REPORTS Q3 2021 RESULTS. * Q3 EARNINGS PER SHARE $1.37. * Q3 SALES $23.3 BILLION VERSUS REFINITIV IBES ESTIMATE OF $23.78 BILLION. * Q3 ADJUSTED EARNINGS PER SHARE $2.60. * Q3 EARNINGS PER SHARE ESTIMATE $2.36 -- REFINITIV IBES DATA. * J&J - COMPANY INCREASING 2021 FULL-YEAR GUIDANCE. * J&J - QTRLY WORLDWIDE COVID-19 VACCINE SALES $502 MILLION.

  12. Show article details.

    J&J keeps vaccine sales outlook unchanged after third-quarter miss

    Reuters – 6:31 AM ET 10/19/2021

    -Johnson & Johnson (JNJ) on Tuesday reported lower-than- expected quarterly revenue after sales of its COVID-19 vaccine missed Wall Street estimates following a string of production setbacks.

  13. Show article details.

    Johnson & Johnson maintains 2021 sales forecast for COVID-19 vaccine

    Reuters – 6:28 AM ET 10/19/2021

    Johnson & Johnson (JNJ) on Tuesday maintained its 2021 sales forecast for its COVID-19 vaccine at $2.5 billion and reported $502 million in sales of the single-dose shot in the third quarter.

  14. Show article details.

    Johnson & Johnson Reports Q3 2021 Results

    PR Newswire – 6:25 AM ET 10/19/2021

    NEW BRUNSWICK, N.J., Oct. 19, 2021  Johnson & Johnson (JNJ) today announced results for third-quarter 2021.  .  . THIRD QUARTER 2021 SEGMENT COMMENTARY: Consumer HealthConsumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, increased 5.7%* primarily driven by over-the-counter products.

  15. Show article details.

    Marketmind: Fast and furious

    Reuters – 3:01 AM ET 10/19/2021

    A look at the day ahead from Sujata Rao. It took two weeks for UK money markets to go from expecting no interest rate rises this year to betting on a cumulative 35 basis-point moves in November and December. Besides Britain, some are placing bets on a September 2022 Fed rate hike; a month ago, no move was predicted before 2023. So, is it justified?

  16. Show article details.

    MORNING BID-Fast and furious

    Reuters – 2:54 AM ET 10/19/2021

    A look at the day ahead from Sujata Rao It took two weeks for UK money markets to go from expecting no interest rate rises this year to betting on a cumulative 35 basis-point moves in November and December. Besides Britain, some are placing bets on a September 2022 Fed rate hike; a month ago, no move was predicted before 2023. So, is it justified?

  17. Show article details.

    PRESS DIGEST- Wall Street Journal - Oct 19

    Reuters – 1:18 AM ET 10/19/2021

    The following are the top stories in the Wall Street Journal. - The U.S. Food and Drug Administration is moving to soon allow people to receive booster shots that are different from their first COVID-19 vaccine doses, people familiar with the matter said. https://on.wsj.com/30G1yID.

  18. Show article details.

    U.S. FDA to allow mixing and matching of COVID-19 boosters- NYT

    Reuters – 6:09 PM ET 10/18/2021

    The U.S. Food and Drug Administration is planning to allow mixing and matching of booster shots of COVID-19 vaccines in the country, the New York Times reported on Monday, citing people familiar with the agency's plans.

  19. Show article details.

    U.S. administers 408.8 mln doses of COVID-19 vaccines - CDC

    Reuters – 5:10 PM ET 10/18/2021

    The United States has administered 408,797,942 doses of COVID-19 vaccines in the country as of Monday morning and distributed 494,655,075 doses, the U.S. Centers for Disease Control and Prevention said. The figures are up from the 408,265,959 vaccine doses the CDC said had gone into arms by Oct. 17.

  20. Show article details.

    US STOCKS-S&P, Nasdaq enjoy boost from big tech firms, Dow ends a hair lower

    Reuters – 4:36 PM ET 10/18/2021

    * Consumer discretionary sector leads S&P gainers. * Utilities lead S&P sector losers. * Disney (DIS) slips after Barclays downgrades to 'equal weight' * Dow down 0.1%, S&P up 0.34%, Nasdaq up 0.84% By Devik Jain, Shreyashi Sanyal and Sinéad Carew.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Oct
    19

    JNJ announced Q3 earnings of $2.60 per share (vs. $2.35)

  • Aug
    23

    JNJ ex-Dividend for $1.06 on 08/23/2021

    • Announce Date: 07/19/2021
    • Record Date: 08/24/2021
    • Pay Date: 09/07/2021
Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.